Characterisation of the binding of amyloid imaging tracers to rodent Aβ fibrils and rodent-human Aβ co-polymers

Biochemical and Biophysical Research Communications

Volumn 347, Issue 3, 2006, Pages 669-677

  Ye, Liang ^a   Morgenstern, Jennifer L ^a   Lamb, Jonathan R ^a   Lockhart, Andrew ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

A Peptide; Alzheimer's disease; Amyloid; Neuroimaging; PET; Senile plaque

Indexed keywords

1 BROMO 2,5 BIS(3 HYDROXYCARBONYL 4 HYDROXY)STYRYLBENZENE; 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; 2 [1 [6 [2 FLUOROETHYL(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE; 2 [4' ([3H]METHYLAMINO)PHENYL] 6 METHYLBENZOTHIAZOLE; 4 N METHYLAMINO 4' HYDROXYSTILBENE; AMYLOID; AMYLOID BETA PROTEIN; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOSE RESPONSE; LIGAND BINDING; MOUSE; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; LIGANDS; MICE; MOLECULAR STRUCTURE; PROTEIN BINDING; SPECTROMETRY, FLUORESCENCE; THIAZOLES; TRITIUM;

MUS MUSCULUS; RODENTIA;

EID: 33746331028     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.126     Document Type: Article

References (34)

1. Pangalos M.N., Jacobsen S.J., and Reinhart P.H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem. Soc. Trans. 33 (2005) 553-558
2. Mathis C.A., Wang Y., and Klunk W.E. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Pharm. Des. 10 (2004) 1469-1492
3. Lockhart A., Ye L., Judd D.B., Merritt A.T., Lowe P., Morgenstern J.L., Hong G., Gee A.D., and Brown J. Evidence for the presence of three distinct binding sites for the thioflavin T class of alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J. Biol. Chem. 280 (2004) 7677-7684
4. Levine III H. Multiple ligand binding sites on A beta(1-40) fibrils. Amyloid 12 (2005) 5-14
5. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., and Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004) 306-319
6. 11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12 (2004) 584-595
7. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., and Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10 (2002) 24-35
8. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 593-600
9. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., Dekosky S.T., Price J.C., and Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25 (2005) 10598-10606
10. Hilbich C., Kisters-Woike B., Reed J., Masters C.L., and Beyreuther K. Human and rodent sequence analogs of Alzheimer's amyloid beta A4 share similar properties and can be solubilized in buffers of pH 7.4. Eur. J. Biochem. 201 (1991) 61-69
11. Otvos Jr. L., Szendrei G.I., Lee V.M., and Mantsch H.H. Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. Eur. J. Biochem. 211 (1993) 249-257
12. Fraser P.E., Nguyen J.T., Inouye H., Surewicz W.K., Selkoe D.J., Podlisny M.B., and Kirschner D.A. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry 31 (1992) 10716-10723
13. Dyrks T., Dyrks E., Masters C.L., and Beyreuther K. Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett. 324 (1993) 231-236
14. Pype S., Moechars D., Dillen L., and Mercken M. Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J. Neurochem. 84 (2003) 602-609
15. van Groen T., and Kadish I. Mouse Ab is deposited in amyloid plaques in APP/PS1 mutant mice. Neurobiol. Aging 25 S2 (2004) 165
16. Hasegawa K., Yamaguchi I., Omata S., Gejyo F., and Naiki H. Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 38 (1999) 15514-15521
17. Frost D., Gorman P.M., Yip C.M., and Chakrabartty A. Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. Eur. J. Biochem. 270 (2003) 654-663
18. Vitek M.P. Radical changes in beta-amyloid form and function. Mol. Chem. Neuropathol. 28 (1996) 49-55
19. Fung J., Frost D., Chakrabartty A., and McLaurin J. Interaction of human and mouse Abeta peptides. J. Neurochem. 91 (2004) 1398-1403
20. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., and Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46 (2003) 2740-2754
21. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., Cole G.M., Small G.W., Huang S.C., and Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 21 (2001) RC189
22. Lee C.W., Zhuang Z.P., Kung M.P., Plossl K., Skovronsky D., Gur T., Hou C., Trojanowski J.Q., Lee V.M., and Kung H.F. Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain. J. Med. Chem. 44 (2001) 2270-2275
23. Ono M., Kung M.P., Hou C., and Kung H.F. Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. Nucl. Med. Biol. 29 (2002) 633-642
24. Ono M., Wilson A., Nobrega J., Westaway D., Verhoeff P., Zhuang Z.P., Kung M.P., and Kung H.F. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl. Med. Biol. 30 (2003) 565-571
25. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
26. Ye L., Morgenstern J.L., Gee A.D., Hong G., Brown J., and Lockhart A. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J. Biol. Chem. 280 (2005) 23599-23604
27. Kung M.P., Hou C., Zhuang Z.P., Skovronsky D., and Kung H.F. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res. 1025 (2004) 98-105
28. Klunk W.E., Jacob R.F., and Mason R.P. Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal. Biochem. 266 (1999) 66-76
29. Levine III H. Mechanism of Abeta(1-40) fibril-induced fluorescence of (trans,trans)-1-bromo-2,5-bis(4-hydroxystyryl)benzene (K114). Biochemistry 44 (2005) 15937-15943
30. Zhuang Z.P., Kung M.P., Hou C., Skovronsky D.M., Gur T.L., Plossl K., Trojanowski J.Q., Lee V.M., and Kung H.F. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J. Med. Chem. 44 (2001) 1905-1914
31. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., Kalback W.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., and Roher A.E. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276 (2001) 12991-12998
32. Kalback W., Watson M.D., Kokjohn T.A., Kuo Y.M., Weiss N., Luehrs D.C., Lopez J., Brune D., Sisodia S.S., Staufenbiel M., Emmerling M., and Roher A.E. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41 (2002) 922-928
33. Kuo Y.M., Emmerling M.R., Woods A.S., Cotter R.J., and Roher A.E. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem. Biophys. Res. Commun. 237 (1997) 188-191
34. Kuo Y.M., Webster S., Emmerling M.R., De Lima N., and Roher A.E. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta 1406 (1998) 291-298